Published Date : Aug 21, 2017
ALBANY, New York, August 21, 2017 – The growth hormone deficiency (GHD) market has been envisaged in a report added by MarketResearchReports.biz to rise at a moderate pace during the forecast period 2016–2026. Titled “Opportunity Analyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026,” the report has been of the opinion that the market could expand at a CAGR of 3.9% during the course of the 10-year forecast period. According to the authors of the report, the market had been estimated to rake in a US$1.42 bn during the 2016 GHD sales in the seven major markets (7MM), possibly, the U.S., France, Germany, Italy, Spain, the U.K., and Israel. By the final forecast year, the market could attract an approximate sales of US$2.08 bn.
A top-line 10-year forecast has been provided in the report for three key geographies, viz. the U.S., five European Union (5 EU) countries, possibly, the U.K., France, Germany, Italy, and Spain, and Japan. However, amongst the three geographical markets for GHD, the U.S. could showcase a faster growth while accounting for a nearly 69.0% of the global sales by 2026 and registering a 4.4% CAGR for the aforementioned forecast timeframe. The growth of the U.S. GHD market has been predicted to be primarily on account of the overly expected advents of long-acting growth hormones (GHs). The ensuing rise in adhere to and compliance with therapy has also been foreseen to contribute toward the growth of the GHD market in the U.S.
For Sample Copy, click here: https://www.marketresearchreports.biz/sample/sample/1142783
On the other hand, the U.S. GHD market could be influenced by payer preferences. One of the factors anticipated to restrict the growth of the general market are strict insurance and regulatory policies. As for the U.S. market, growth could be hindered by perpetual negotiations between payers and distributors. Furthermore, it could be challenging for new players to cement their position in the overall market post the launch of long-acting GHs.
Having that mentioned, the 216-page opportunity analyzer report has identified a number of favorable prospects for players to rise above the challenges. Under the unmet needs and opportunity assessment section, the report has put forth seven significant factors deemed important for countering the challenges in the GHD market. These are improved way of measuring adherence, safer treatment for cancer survivors, simpler and safer diagnostic test, early diagnosis, insurance policies that impact patient access, disease awareness and physician education, and improved adherence to therapy.
Besides providing a profound reports of key drivers, restraints, and opportunities, the authors of the report have shed light upon some of the critical trends that could play a major part in the growth of the GHD market. In order to offer a qualitative evaluation of its implications, each trend of the market has been independently researched.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org